https://www.accordbiopharma.com/news/accord-biopharma-announces-commercial-availability-of-denosumab-biosimilars-osvyrti-denosumab-desu-and-jubereq-denosumab-desu/ 2026-09-18T12:30:04+00:00 https://www.accordbiopharma.com/news/fda-approves-ennumo-pegfilgrastim-pccg-accord-biopharmas-second-pegfilgrastim-biosimilar-to-neulasta-pegfilgrastim/ 2026-09-18T12:30:04+00:00 https://www.accordbiopharma.com/news/fda-approves-immgolis-golimumab-sldi-and-immgolis-intri-golimumab-sldi-first-biosimilars-to-simponi-golimumab-and-simponi-aria-golimumab-accord-biopharma-to-lea/ 2026-09-18T12:30:05+00:00 https://www.accordbiopharma.com/news/fda-approves-filkri-filgrastim-laha-accord-biopharmas-biosimilar-to-neupogen-filgrastim/ 2026-09-18T12:30:06+00:00 https://www.accordbiopharma.com/news/accord-biopharmas-imuldosa-ustekinumab-srlf-now-preferred-under-cigna-healthcare-commercial-plans/ 2026-09-18T12:30:06+00:00 https://www.accordbiopharma.com/news/accord-biopharmas-hercessi-trastuzumab-strf-gains-preferred-status-on-express-scripts-national-commercial-formularies/ 2026-09-18T12:30:07+00:00 https://www.accordbiopharma.com/news/accord-biopharmas-imuldosa-ustekinumab-srlf-added-to-express-scripts-national-commercial-formularies/ 2026-09-18T12:30:07+00:00 https://www.accordbiopharma.com/news/accord-biopharma-inc-announces-fda-approval-of-denosumab-biosimilars-osvyrti-denosumab-desu-and-jubereq-denosumab-desu/ 2026-09-18T12:30:08+00:00 https://www.accordbiopharma.com/news/accord-biopharma-announces-commercial-launch-of-imuldosa-ustekinumab-srlf-prefilled-syringes-at-lowest-wac-price-among-branded-biosimilars-to-stelara-ustekinumab/ 2026-09-18T12:30:09+00:00 https://www.accordbiopharma.com/news/accord-biopharma-inc-announces-completion-of-udenyca-pegfilgrastim-cbqv-franchise-acquisition-from-coherus-biosciences-inc-expanding-u-s-biosimilar-portfolio/ 2026-09-18T12:30:09+00:00 https://www.accordbiopharma.com/news/accord-biopharma-inc-recognizes-milestone-as-more-than-10000-patients-gain-access-to-camcevi-leuprolide/ 2026-09-18T12:30:10+00:00 https://www.accordbiopharma.com/news/accord-biopharma-strengthens-pipeline-through-exclusive-u-s-licensing-agreement-with-bio-thera-for-bat2506-a-proposed-golimumab-biosimilar/ 2026-09-18T12:30:10+00:00 https://www.accordbiopharma.com/news/accord-biopharma-announces-agreement-by-intas-pharmaceuticals-ltd-to-acquire-udenyca-pegfilgrastim-cbqv-business-from-coherus-biosciences-inc-unlocking-potential-for-continued-u-s-growth/ 2026-09-18T12:30:11+00:00 https://www.accordbiopharma.com/news/fda-approves-imuldosa-ustekinumab-srlf-accord-biopharmas-biosimilar-to-stelara-ustekinumab-for-the-treatment-of-chronic-inflammatory-conditions/ 2026-09-18T12:30:12+00:00 https://www.accordbiopharma.com/news/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-420mg-strength-of-hercessi-trastuzumab-strf-a-biosimilar-to-herceptin-trastuzumab-for-the-treatment-of/ 2026-09-18T12:30:12+00:00 https://www.accordbiopharma.com/news/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-hercessi-trastuzumab-strf-a-biosimilar-to-herceptin-trastuzumab-for-the-treatment-of-several-forms-of-h/ 2026-09-18T12:30:13+00:00 https://www.accordbiopharma.com/news/accord-biopharma-inc-announces-u-s-fda-acceptance-of-biologics-license-application-for-proposed-stelara-biosimilar-dmb-3115/ 2026-09-18T12:30:14+00:00 https://www.accordbiopharma.com/news/accord-biopharma-announces-u-s-fda-acceptance-of-biologics-license-application-for-proposed-biosimilar-trastuzumab-hlx02/ 2026-09-18T12:30:14+00:00 https://www.accordbiopharma.com/news/accord-biopharma-announces-accordconnects-inventory-management-system-for-hospitals-and-healthcare-practices/ 2026-09-18T12:30:15+00:00 https://www.accordbiopharma.com/news/accord-biopharma-partners-with-storymd-to-deliver-advanced-prostate-cancer-educational-content-to-clinicians-and-patients/ 2026-09-18T12:30:15+00:00 https://www.accordbiopharma.com/news/accord-biopharma-and-eversana-announce-partnership-to-support-the-launch-of-camcevi-for-the-treatment-of-advanced-prostate-cancer-in-adults-in-the-u-s/ 2026-09-18T12:30:16+00:00 https://www.accordbiopharma.com/news/accord-biopharma-in-partnership-with-foresee-pharmaceuticals-launches-camcevi-leuprolide-injection-emulsion-in-the-u-s-for-the-treatment-of-advanced-prostate-cancer-in-adults/ 2026-09-18T12:30:16+00:00 https://www.accordbiopharma.com/news/accord-biopharma-announces-u-s-launch-for-camcevi-leuprolide-injection-emulsion-for-the-treatment-of-advanced-prostate-cancer-in-adults/ 2026-09-18T12:30:17+00:00 https://www.accordbiopharma.com/news/accord-biopharma-announces-new-executive-leadership-in-commercialization-and-marketing/ 2026-09-18T12:30:18+00:00